| Literature DB >> 27494736 |
Oksana Sirenko1, Michael K Hancock2, Jayne Hesley1, Dihui Hong1, Avrum Cohen1, Jason Gentry1, Coby B Carlson2, David A Mann2.
Abstract
Cell models are becoming more complex to better mimic the in vivo environment and provide greater predictivity for compound efficacy and toxicity. There is an increasing interest in exploring the use of three-dimensional (3D) spheroids for modeling developmental and tissue biology with the goal of accelerating translational research in these areas. Accordingly, the development of high-throughput quantitative assays using 3D cultures is an active area of investigation. In this study, we have developed and optimized methods for the formation of 3D liver spheroids derived from human iPS cells and used those for toxicity assessment. We used confocal imaging and 3D image analysis to characterize cellular information from a 3D matrix to enable a multi-parametric comparison of different spheroid phenotypes. The assay enables characterization of compound toxicities by spheroid size (volume) and shape, cell number and spatial distribution, nuclear characterization, number and distribution of cells expressing viability, apoptosis, mitochondrial potential, and viability marker intensities. In addition, changes in the content of live, dead, and apoptotic cells as a consequence of compound exposure were characterized. We tested 48 compounds and compared induced pluripotent stem cell (iPSC)-derived hepatocytes and HepG2 cells in both two-dimensional (2D) and 3D cultures. We observed significant differences in the pharmacological effects of compounds across the two cell types and between the different culture conditions. Our results indicate that a phenotypic assay using 3D model systems formed with human iPSC-derived hepatocytes is suitable for high-throughput screening and can be used for hepatotoxicity assessment in vitro.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27494736 PMCID: PMC5003004 DOI: 10.1089/adt.2016.729
Source DB: PubMed Journal: Assay Drug Dev Technol ISSN: 1540-658X Impact factor: 1.738
Comparison of Compound Responses Between 3D and 2D Cultures of iPSC-Derived Hepatocytes
| iCell hepatocytes | |||
|---|---|---|---|
| Compounds | IC50 (μM)[ | IC50 (μM) | Compound description |
| Toxic substances | |||
| TAB | 1.69 ± 0.082 | 1.22 ± 1.02 | Toxin |
| Methyl mercury | 2.82 ± 0.49 | 5.05 ± 1.31 | Toxin |
| Fuzariotoxin | 0.481[ | 3.75 | Toxin |
| Aflatoxin B1 | 0.595 ± 0.145 | 1.7 | Toxin |
| Aflatoxin G1 | 7.78 ± 2.13 | 9.45 ± 2.01 | Toxin |
| Rotenone | 21.4 ± 6.9 | n.d.[ | Pesticide |
| Anti-proliferative agents | |||
| Mitoxantrone | Topoisomerase II inhibitor | ||
| Daunorubicin | 0.671 ± 0.046 | 0.5 | DNA-intercalator, anti-cancer |
| Idarubicin | 1.11 | 0.94 | DNA-intercalator, anti-cancer |
| Doxorubicin·HCl | 5.69 ± 4.04 | 2.17 ± 0.08 | DNA-intercalator, anti-cancer |
| Staurosporine | 0.91 ± 0.12 | 1.71 ± 0.87 | Kinase inhibitor, apoptosis inducer |
| Mitomycin C | 2.28 ± 0.25 | 2.36 ± 0.65 | DNA-intercalator, anti-cancer |
| Other drugs | |||
| Quinacrine | 1.029 ± 0.212 | 2.52 | Anti-malaria |
| Coralgil | 1.24 | 6.71 | Inducer of steatosis |
| Puromycin | 3.82 | 7.2 ± 11.2 | Protein synthesis inhibitor |
| Amlodipine | 4.12 | 30.2 | Ca blocker |
| rac Perhexiline Maleate | 6.36 ± 0.15 | 9.89 | Mitochondria inhibitor |
| Tamoxifen | 12.4 | 10.23 | Estrogen receptor antagonist |
| Miconazole nitrate | 13.71 ± 0.789 | 103.1 ± 132 | Anti-fungal |
| Fluphenazine di·HCl | 13.0 ± 0.824 | 29.5 | Anti-psychotic |
| Paroxetine | 14.73 ± 3.92 | 30.4 | Antidepressant |
| Thioridazine | 15.83 ± 4.47 | 31.4 | Anti-psychotic |
| Chloroquine | 18.60 ± 0.247 | 38.5 | Anti-malaria |
| Ketoconazole | 20.4 ± 10.7 | 61.0 ± 46.2 | Anti-fungal |
| Amiodarone·HCl | 22.6 ± 9.68 | 15.3 ± 18.3 | Anti-arrhythmia, autophagy inducer |
| Paclitaxel | 26.2 ± 6.39 | No tox (100)[ | Microtubule inhibitor |
| Fluoxetine | 28.9 | 10.17 ± 0.321 | Antidepressant |
| Imatinib | 36.8 | n.d. | Kinase inhibitor |
| Pimozide | 35.1 ± 1.39 | 13.5 ± 15.9 | Anti-psychotic |
| Apigenin | 36.9 ± 10.2 | n.d. | Autophagy inducer |
| Haloperidol·HCl | 52.2 ± 21.6 | No tox (100) | Anti-psychotic |
| Isradipine | 168 ± 137 | n.d. | Ca blocker |
| Colchicine | >100[ | >100 | Microtubule inhibitor |
| Tolcapone | >100 | >100 | Parkinson disease drug |
| Doxocycline | >100 | >100 | Antibiotic |
| Retinoic acid | ∼500 | 480 | Retinoic acid receptor agonist |
| Imipramine | No tox (100) | >100 | Antidepressant (TCA) |
| Carboplatin | No tox (500) | No tox (500) | DNA repair, anti-cancer |
| Cytarabine | No tox (1,000) | No tox (1,000) | DNA intercalator, anti-cancer |
| Etoposide | No tox (1,000) | No tox (1,000) | Topoisomerase inhibitor, anti-cancer |
| Phenylbutazone | No tox (100) | No tox (100) | Nonsteroidal anti-inflammatory |
| Acetaminophen | No tox (1,000) | No tox (1,000) | Nonsteroidal anti-inflammatory |
| Negative controls | |||
| Penicillin V potassium salt | No tox (1,000) | No tox (1,000) | Antibiotic |
| Streptomycin sulfate | No tox (1,000) | No tox (1,000) | Antibiotic |
| Aspirin | No tox (1,000) | No tox (1,000) | Anti-inflammatory |
| Ampicillin | No tox (1,000) | No tox (1,000) | Antibiotic |
| Sucrose | No tox (1,000) | No tox (1,000) | Carbohydrate |
| Sorbitol | No tox (1,000) | No tox (1,000) | Carbohydrate |
IC50 values (in μM) measured for tested compounds using number of live cells per spheroid as the readout. Error limits are standard error of the parameter estimate defined from the curve fit.
The undefined standard errors for some parameters indicate that although the curve fits have converged, the uncertainty in the parameter estimates could not be determined.
n.d., not determined.
Difference between 3D and 2D is significant (P < 0.05). Indicated in bold.
“No tox” means that no apparent effects were observed at the highest concentration tested (value in μM in parentheses).
“>100” means that toxic effects (decrease of calcein AM-positive cells) were observed at the highest concentration tested (100 μM), but IC50 values were not determined.
2D, two-dimensional; 3D, three-dimensional; iPSC, induced pluripotent stem cell; TAB, tetraoctylammonium bromide.
Comparison of Compound Responses Between 3D Cultures of HepG2- and iPSC-Derived Hepatocytes
| HepG2, IC50 (μM)[ | iPSC-derived hepatocytes, IC50 (μM) | |
|---|---|---|
| Anti-proliferation agents | ||
| Idarubicin | 0.00513 ± 0.00523 | 1.11 |
| Staurosporine | ||
| Doxorubicin·HCl | 0.008 ± 0.0005 | 5.69 ± 4.04 |
| Mitomycin C | ||
| Paclitaxel | ||
| Cytarabine | 0.307 ± 0.097 | No tox (1,000)[ |
| Etoposide | 4.18 ± 2.99 | No tox (1,000) |
| Carboplatin | 15.82 ± 2.61 | No tox (1,000) |
| Toxic substances | ||
| TAB | ||
| Methyl mercury | ||
| Rotenone | 8.32 ± 4.37 | 21.4 ± 6.94 |
| Other drugs | ||
| Pimozide | ||
| Tamoxifen | 18.7 ± 29.4 | 12.4 ± 13.2 |
| Ketoconazole | 19.2 ± 12.5 | 20.4 ± 10.7 |
| Apigenin | 21.9 ± 13.4 | 36.9 ± 10.18 |
| Isradipine | 22.17 | 168 ± 137 |
| Haloperidol·HCl | 25.08 ± 5.50 | 52.2 ± 21.6 |
| Chloroquine | 33.28 | 18.60 ± 0.247 |
| Amiodarone·HCl | 42.4 ± 8.39 | 22.6 ± 9.68 |
| Imatinib | 178 ± 40.54 | 36.8 |
| Negative controls | ||
| Aspirin | No tox (1,000) | No tox (1,000) |
| Ampicillin | No tox (1,000) | No tox (1,000) |
| Sucrose | No tox (1,000) | No tox (1,000) |
IC50 values (in μM) were determined for tested compounds using number of live cells per spheroid as the readout. Error limits are standard error of the parameter estimate defined from the curve fit.
Differences between HepG2- and iPSC-derived hepatocytes is significant (P < 0.05) for compounds indicated in bold.
“No tox” means that no apparent effects were observed at the highest concentration tested (value in μM in parentheses).